DE60142192D1 - Nanopartikel - Google Patents
NanopartikelInfo
- Publication number
- DE60142192D1 DE60142192D1 DE60142192T DE60142192T DE60142192D1 DE 60142192 D1 DE60142192 D1 DE 60142192D1 DE 60142192 T DE60142192 T DE 60142192T DE 60142192 T DE60142192 T DE 60142192T DE 60142192 D1 DE60142192 D1 DE 60142192D1
- Authority
- DE
- Germany
- Prior art keywords
- carbohydrate
- nanoparticles
- immobilising
- therapeutics
- studying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0025414.4A GB0025414D0 (en) | 2000-10-16 | 2000-10-16 | Nanoparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60142192D1 true DE60142192D1 (de) | 2010-07-01 |
Family
ID=9901442
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60117828T Expired - Lifetime DE60117828T2 (de) | 2000-10-16 | 2001-10-16 | Nanopartikel |
DE60142192T Expired - Lifetime DE60142192D1 (de) | 2000-10-16 | 2001-10-16 | Nanopartikel |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60117828T Expired - Lifetime DE60117828T2 (de) | 2000-10-16 | 2001-10-16 | Nanopartikel |
Country Status (10)
Country | Link |
---|---|
US (3) | US7364919B2 (de) |
EP (2) | EP1326589B1 (de) |
JP (2) | JP4467882B2 (de) |
AT (2) | ATE319436T1 (de) |
AU (2) | AU2001294068B2 (de) |
CA (1) | CA2424734C (de) |
DE (2) | DE60117828T2 (de) |
ES (2) | ES2346319T5 (de) |
GB (1) | GB0025414D0 (de) |
WO (1) | WO2002032404A2 (de) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7871597B2 (en) | 1999-04-09 | 2011-01-18 | Amag Pharmaceuticals, Inc. | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
FI118061B (fi) * | 2001-09-24 | 2007-06-15 | Beanor Oy | Menetelmä ja bioanturi analyysiä varten |
FI115166B (fi) * | 2001-12-31 | 2005-03-15 | Biofons Oy | Diagnostisia menetelmiä |
US7361821B2 (en) | 2002-09-20 | 2008-04-22 | Intel Corporation | Controlled alignment of nanobarcodes encoding specific information for scanning probe microscopy (SPM) reading |
JP4520857B2 (ja) | 2002-09-20 | 2010-08-11 | インテル・コーポレーション | 走査型プローブ顕微鏡検査(spm)読取用の特定の情報をエンコードするナノバーコードの制御された整列 |
US7695738B2 (en) * | 2003-02-19 | 2010-04-13 | Academia Sinica | Carbohydrate encapsulated nanoparticles |
WO2005010481A2 (en) * | 2003-06-03 | 2005-02-03 | The Regents Of The University Of California | Preparation and use of gold glyconanoparticles |
GB0313259D0 (en) | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
WO2005044861A1 (en) * | 2003-10-31 | 2005-05-19 | Wyeth Holdings Corporation | Polysaccharides of helicobacter pylori |
AU2004289210B2 (en) * | 2003-11-05 | 2010-07-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
ES2242528B1 (es) * | 2004-03-25 | 2006-12-01 | Consejo Sup. Investig. Cientificas | Nanoparticulas magneticas de metales nobles. |
US20080213177A1 (en) | 2004-05-24 | 2008-09-04 | Thomas William Rademacher | Nanoparticles Comprising Rna Ligands |
GB0411537D0 (en) * | 2004-05-24 | 2004-06-23 | Midatech Ltd | Nanoparticles comprising rna ligands |
US20070249063A1 (en) * | 2004-08-30 | 2007-10-25 | Deshong Philip R | Biosensors |
ES2625905T3 (es) * | 2004-10-01 | 2017-07-20 | Midatech Ltd. | Nanopartículas que comprenden antígenos y adyuvantes capaces de estimular linfocitos T cooperadores |
JP4550555B2 (ja) * | 2004-11-17 | 2010-09-22 | 国立大学法人 東京医科歯科大学 | 量子ドット(Qdot)−ナノゲル複合体の調製 |
JP2006182673A (ja) * | 2004-12-27 | 2006-07-13 | Kenji Yamamoto | マーカー付き医薬 |
JP4484151B2 (ja) * | 2005-03-28 | 2010-06-16 | 国立大学法人滋賀大学 | ヒト血液型試薬 |
US8845927B2 (en) | 2006-06-02 | 2014-09-30 | Qd Vision, Inc. | Functionalized nanoparticles and method |
US9297092B2 (en) | 2005-06-05 | 2016-03-29 | Qd Vision, Inc. | Compositions, optical component, system including an optical component, devices, and other products |
EP2278303A3 (de) * | 2005-06-10 | 2012-02-22 | Life Technologies Corporation | Verfahren und Vorrichtung für die genetische Multiplex-Analyse |
US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US9034380B2 (en) | 2005-08-04 | 2015-05-19 | Midatech Ltd. | Nanoparticles comprising antibacterial ligands |
GB0517077D0 (en) * | 2005-08-19 | 2005-09-28 | Isis Innovation | Imaging agent |
JP4670659B2 (ja) * | 2006-01-25 | 2011-04-13 | 住友電気工業株式会社 | 蛍光標識金属粉末、ならびに該蛍光標識金属粉末を含有する異方導電膜、実装品 |
WO2008123844A2 (en) * | 2006-02-08 | 2008-10-16 | University Of Toledo | System for detecting nanoparticles using modulated surface plasmon resonance (mspr) |
US8849087B2 (en) * | 2006-03-07 | 2014-09-30 | Qd Vision, Inc. | Compositions, optical component, system including an optical component, devices, and other products |
TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
US9212056B2 (en) | 2006-06-02 | 2015-12-15 | Qd Vision, Inc. | Nanoparticle including multi-functional ligand and method |
WO2007147823A1 (en) * | 2006-06-20 | 2007-12-27 | Bracco Imaging Spa | Method for the preparation of specific antibodies against saccharidic antigens |
WO2008063662A2 (en) * | 2006-11-21 | 2008-05-29 | Black Lion Pharmaceuticals | Gold (iii) chloride compositions for cancer |
CA2591496C (en) | 2006-12-18 | 2014-09-02 | Japan Science And Technology Agency | Method of measuring interaction between biomaterial and sugar chain, method of evaluating biomaterial in sugar chain selectivity, method of screening biomaterial, method of patterning biomaterials, and kits for performing these methods |
US20080317768A1 (en) * | 2007-06-21 | 2008-12-25 | Boeing Company | Bioconjugated nanoparticles |
ES2320837B1 (es) | 2007-07-26 | 2010-03-04 | Consejo Superior De Investigaciones Cientificas | Dispositivo de hipertermia y su utilizacion con nanoparticulas. |
US8916135B2 (en) | 2007-08-22 | 2014-12-23 | Colorado School Of Mines | Lanthanide nanoparticle conjugates and uses thereof |
EP2033660A1 (de) * | 2007-09-05 | 2009-03-11 | Freie Universität Berlin | Funktionalisierte Nanopartikel zur Hemmung Selectin-vermittelter Zelladhäsion |
GB0718843D0 (en) | 2007-09-26 | 2007-11-07 | Cancer Rec Tech Ltd | Materials and methods relating to modifying the binding of antibodies |
DE102007055386B4 (de) * | 2007-11-20 | 2015-07-16 | Boehringer Ingelheim Vetmedica Gmbh | Verfahren zur Kalibrierung eines Sensorelements |
KR20100107437A (ko) * | 2007-12-28 | 2010-10-05 | 내셔널 유니버시티 코포레이션 쉬가 유니버시티 어브 메디칼 사이언스 | 금나노 입자 조성물, dna칩, 근적외선 흡수재, 약물전달시스템(dds)용 약물 담체, 착색제, 바이오센서, 화장품, 생체내 진단용 조성물 및 치료용 조성물 |
EP2123269A1 (de) * | 2008-05-21 | 2009-11-25 | Freie Universität Berlin | Mit sulfatierten Aminalkoholen funktionalisierte Nanopartikel zur Hemmung selectinvermittelter Zelladhäsion |
WO2010096464A1 (en) | 2009-02-18 | 2010-08-26 | Boyes Stephen G | Gold/lanthanide nanoparticle conjugates and uses thereof |
WO2010087912A1 (en) * | 2009-01-30 | 2010-08-05 | University Of Utah Research Foundation | Hydrogels crosslinked with gold nanoparticles and methods of making and using thereof |
EA022699B1 (ru) | 2009-05-27 | 2016-02-29 | Селекта Байосайенсиз, Инк. | НАЦЕЛЕННЫЕ СИНТЕТИЧЕСКИЕ НАНОНОСИТЕЛИ С pH-ЧУВСТВИТЕЛЬНЫМ ВЫСВОБОЖДЕНИЕМ ИММУНОМОДУЛИРУЮЩИХ СРЕДСТВ |
EA201592264A1 (ru) | 2009-08-26 | 2016-08-31 | Селекта Байосайенсиз, Инк. | Композиции, которые индуцируют хелперное действие т-клеток |
US10081542B2 (en) | 2010-04-20 | 2018-09-25 | University of Florida Research Foundation, lnc. | Nanozymes, methods of making nanozymes, and methods of using nanozymes |
US8962345B2 (en) * | 2010-05-21 | 2015-02-24 | The United States Of America As Represented By The Secretary Of Commerce | Method of characterizing glycans attached to glycoproteins |
CN107029223A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
US8974826B2 (en) | 2010-06-10 | 2015-03-10 | Monosol Rx, Llc | Nanoparticle film delivery systems |
EP2579898B1 (de) | 2010-06-10 | 2019-01-09 | Midatech Ltd. | Peptidtragende nanopartikel |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
US20120301498A1 (en) | 2011-04-29 | 2012-11-29 | Selecta Biosciences, Inc. | Controlled release of immunosuppressants from synthetic nanocarriers |
KR20140050698A (ko) | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체 |
JP5754309B2 (ja) * | 2011-09-02 | 2015-07-29 | コニカミノルタ株式会社 | 表面プラズモン励起増強蛍光分光法を利用して蛍光量を測定する定量分析方法ならびにそれに用いられる定量分析用キットおよびアナライト解離抑制剤 |
JP2014531427A (ja) | 2011-09-07 | 2014-11-27 | ミダテック リミテッド | ナノ粒子腫瘍ワクチン |
BR112014005242B1 (pt) | 2011-09-07 | 2022-07-26 | Midatech Limited | Nanopartículas com peptídeos, composição, vacina, usos das mesmas para o tratamento de câncer ou de uma infecção por patógenos e métodos para gerar uma resposta de linfócitos t citotóxicos e para produzir as ditas nanopartículas |
US9772305B2 (en) | 2011-09-15 | 2017-09-26 | Arizona Board Of Regents On Behalf Of Arizona State University | System and method for small molecule detection |
GB201301991D0 (en) | 2013-02-05 | 2013-03-20 | Midatech Ltd | Permeation enhanced active-carrying nanoparticles |
GB201302427D0 (en) | 2013-02-12 | 2013-03-27 | Midatech Ltd | Nanoparticle delivery compositions |
GB201303787D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticle peptide compositions |
GB201303771D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticles peptide compositions |
WO2014145205A2 (en) | 2013-03-15 | 2014-09-18 | St. Jude Children's Research Hospital | Methods and compositions of p27kip1 transcription modulators |
KR101329646B1 (ko) | 2013-05-02 | 2013-11-14 | 주식회사 지니스 | 표적지향증폭형 항암나노입자 및 이의 제조방법 |
BR122020023215B1 (pt) | 2013-05-03 | 2022-11-22 | Selecta Biosciences, Inc | Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
MX2015016691A (es) | 2013-06-04 | 2016-04-04 | Selecta Biosciences Inc | Administracion repetida de inmunoterapeuticos especificos de antigeno no inmunosupresores. |
TW201521762A (zh) | 2013-08-14 | 2015-06-16 | Univ Florida | 奈米酶、製備奈米酶的方法、以及使用奈米酶的方法 |
JP6545177B2 (ja) | 2013-09-29 | 2019-07-17 | セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド | 抗菌薬としてのアリール置換アミノメチルスペクチノマイシン類似体 |
GB201401706D0 (en) | 2014-01-31 | 2014-03-19 | Midatech Ltd | Nanoparticle-insulin and insulin analogue compositions |
CA2945945C (en) | 2014-04-15 | 2023-10-03 | The Regents Of The University Of California | Bi-terminal pegylated integrin-binding peptides and methods of use thereof |
EP3160453A1 (de) | 2014-06-25 | 2017-05-03 | Selecta Biosciences, Inc. | Verfahren und zusammensetzungen zur behandlung mit synthetischen nanoträgern und immun-checkpoint-hemmern |
US9910035B1 (en) | 2014-07-16 | 2018-03-06 | Verily Life Sciences Llc | Polyvalent functionalized nanoparticle-based in vivo diagnostic system |
IL292574A (en) | 2014-09-07 | 2022-06-01 | Selecta Biosciences Inc | Methods and preparations for attenuating immune responses in an antiviral transfer system |
US10688125B2 (en) | 2014-12-23 | 2020-06-23 | Midatech Ltd. | Nanoparticles and their use in cancer therapy |
KR102588589B1 (ko) * | 2015-05-18 | 2023-10-16 | 히데미 카키하라 | 항균 물질 및 액상 항균제 및 액상 항균제의 제조 방법 |
US20180161340A1 (en) | 2015-06-18 | 2018-06-14 | St. Jude Children's Research Hospital | Methods and compositions for the prevention and treatment of hearing loss |
GB2541166A (en) | 2015-07-24 | 2017-02-15 | Midatech Ltd | Nanoparticle-based liver-targeting therapy and imaging |
US20170157215A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
CN109152819A (zh) | 2016-03-11 | 2019-01-04 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
PT3448364T (pt) | 2016-04-29 | 2022-05-04 | Icahn School Med Mount Sinai | Direcionamento do sistema imunitário inato para induzir uma tolerância a longo prazo e para resolver a acumulação de macrófagos na aterosclerose |
CA3038089A1 (en) | 2016-09-27 | 2018-04-05 | Selecta Biosciences, Inc. | Recombinant immunotoxins for use in the treatment of cancer |
EP3565590A1 (de) | 2017-01-03 | 2019-11-13 | Emergex Vaccines Holdings Limited | Universelle grippeimpfstoffzusammensetzung |
JP2020506890A (ja) | 2017-01-07 | 2020-03-05 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. | 合成ナノキャリアにカップリングした免疫抑制剤のパターン化された投与 |
GB201701745D0 (en) | 2017-02-02 | 2017-03-22 | Midatech Ltd | Nanoparticle-based liver-targeting therapy and imaging |
JP2020510687A (ja) | 2017-03-11 | 2020-04-09 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. | 抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物 |
US10543231B2 (en) | 2017-05-19 | 2020-01-28 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
GB2563602B (en) | 2017-06-19 | 2022-06-08 | Middlesex Univ Higher Education Corporation | Method and apparatus for imaging |
SG11202002044WA (en) | 2017-09-21 | 2020-04-29 | Emergex Vaccines Holding Ltd | MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus |
EP3694543A1 (de) | 2017-10-13 | 2020-08-19 | Selecta Biosciences, Inc. | Verfahren und zusammensetzungen zur abschwächung der igm-reaktionen auf antivirale transfervektoren |
CN111565746A (zh) | 2018-01-06 | 2020-08-21 | 埃默杰克斯疫苗控股有限公司 | 用于预防和治疗多种黄病毒的mhc i类相关肽 |
CN112292148A (zh) | 2018-03-29 | 2021-01-29 | 埃默杰克斯疫苗控股有限公司 | 疫苗组合物 |
US20210283237A1 (en) | 2018-03-29 | 2021-09-16 | Emergex Vaccines Holding Limited | Vaccine compositions |
CA3099643A1 (en) | 2018-05-18 | 2019-11-21 | Emergex Vaccines Holding Limited | Reverse peptide vaccine |
WO2020018587A1 (en) | 2018-07-16 | 2020-01-23 | Selecta Biosciences, Inc. | Methods and compositions of mma constructs and vectors |
CN112771070A (zh) | 2018-07-16 | 2021-05-07 | 西莱克塔生物科技公司 | Otc构建体和载体的方法和组合物 |
GB201819430D0 (en) | 2018-11-29 | 2019-01-16 | Midatech Ltd | Therapeutic compounds, nanoparticles and uses thereof |
GB201820470D0 (en) | 2018-12-14 | 2019-01-30 | Midatech Ltd | Antifolate-carrying nanoparticles and their use in medicine |
GB201820471D0 (en) | 2018-12-14 | 2019-01-30 | Midatech Ltd | Nanoparticle-based therapy of inflammatory disorders |
KR20220004121A (ko) | 2019-04-28 | 2022-01-11 | 셀렉타 바이오사이언시즈, 인크. | 바이러스 전달 벡터에 대한 기존의 면역을 갖는 대상체의 치료 방법 |
BR112021023594A2 (pt) | 2019-05-28 | 2022-02-08 | Selecta Biosciences Inc | Métodos e composições para resposta imune de vetor de transferência antiviral atenuada |
CA3138071A1 (en) | 2019-06-04 | 2020-12-10 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
US11890299B2 (en) | 2019-06-27 | 2024-02-06 | Hologic, Inc. | Ablation agent and methods of use |
CN110755640B (zh) * | 2019-10-21 | 2022-06-10 | 浙江师范大学 | 一种金铂复合纳米诊疗剂的制备方法及应用 |
JP2022553345A (ja) | 2019-10-21 | 2022-12-22 | セレクタ バイオサイエンシーズ インコーポレーテッド | 肝疾患および肝障害を処置するための方法および組成物 |
EP4054531A1 (de) | 2019-11-08 | 2022-09-14 | Selecta Biosciences, Inc. | Formulierungen und dosen von pegylierter uricase |
JP2023506891A (ja) | 2019-12-18 | 2023-02-20 | エフ. ホフマン-ラ ロシュ エージー. | 連続的な標識スキームを使用した合成による配列決定方法 |
US20210290601A1 (en) | 2020-02-26 | 2021-09-23 | Selecta Biosciences, Inc. | Methods and compositions using synthetic nanocarriers comprising immunosuppressant |
CA3180166A1 (en) | 2020-04-14 | 2021-10-21 | Selecta Biosciences, Inc. | Methods and compositions for inducing autophagy |
GB202008250D0 (en) | 2020-06-02 | 2020-07-15 | Emergex Vaccines Holding Ltd | Diagnosis, prevention and treatment of coronavirus infection |
CN111590087B (zh) * | 2020-06-04 | 2023-04-18 | 安徽医科大学 | 荧光金纳米簇的制备方法、制得的荧光金纳米簇及其应用 |
WO2022098901A1 (en) | 2020-11-04 | 2022-05-12 | Selecta Biosciences, Inc. | Compositions for reducing immune responses against immunoglobulin proteases |
AU2022206197A1 (en) | 2021-01-05 | 2023-07-13 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
EP4294435A1 (de) | 2021-02-16 | 2023-12-27 | Emergex Vaccines Holding Limited | Reverse peptide aus coronavirus für immunogene zwecke |
CN113059177A (zh) * | 2021-03-05 | 2021-07-02 | 江苏师范大学 | 一种金/银/金核壳结构的纳米粒子及其合成方法 |
JP2024511067A (ja) | 2021-03-19 | 2024-03-12 | トレインド セラピューティクス ディスカバリー,インコーポレーテッド | 訓練された免疫を調節するための化合物およびその使用方法 |
JP2024514577A (ja) | 2021-04-09 | 2024-04-02 | セレクタ バイオサイエンシーズ インコーポレーテッド | 免疫寛容を増強するために高親和性il-2受容体アゴニストと組み合わせて免疫抑制剤を含む合成ナノキャリア |
WO2022253917A1 (en) | 2021-06-02 | 2022-12-08 | Emergex Vaccines Holding Limited | Human coronavirus 229e derived peptides |
CN113500199B (zh) * | 2021-06-10 | 2022-11-08 | 浙江大学 | 一种基于金铂双金属活性氧自生成纳米材料的制备方法及其产品和应用 |
US20230140196A1 (en) | 2021-10-12 | 2023-05-04 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
WO2023086615A1 (en) | 2021-11-14 | 2023-05-19 | Selecta Biosciences, Inc. | Multiple dosing with viral vectors |
US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023172628A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
WO2023183568A1 (en) | 2022-03-25 | 2023-09-28 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents |
US20230381277A1 (en) | 2022-04-08 | 2023-11-30 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
WO2024036324A1 (en) | 2022-08-11 | 2024-02-15 | Selecta Biosciences, Inc. | Compositions and methods related to immunoglobulin proteases and fusions thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7807532A (nl) * | 1978-07-13 | 1980-01-15 | Akzo Nv | Metaal-immunotest. |
WO1983000173A1 (en) | 1981-07-02 | 1983-01-20 | Eynon, David, Leslie | Flow box |
US4501726A (en) * | 1981-11-12 | 1985-02-26 | Schroeder Ulf | Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof |
SE8704157L (sv) | 1987-10-26 | 1989-04-27 | Carbomatrix Ab C O Ulf Schroed | Superparamagnetiska partiklar och foerfarande foer framstaellning daerav samt anvaendning |
US5178882A (en) * | 1990-06-22 | 1993-01-12 | The Regents Of The University Of California | Viral decoy vaccine |
US5248772A (en) * | 1992-01-29 | 1993-09-28 | Coulter Corporation | Formation of colloidal metal dispersions using aminodextrans as reductants and protective agents |
JP3337075B2 (ja) * | 1992-08-05 | 2002-10-21 | 名糖産業株式会社 | 小粒子径水溶性カルボキシ多糖−磁性酸化鉄複合体 |
WO1995031220A1 (fr) | 1994-05-12 | 1995-11-23 | Otsuka Pharmaceutical Co., Ltd. | Agent de contraste pour imagerie par resonance magnetique |
FR2777193B1 (fr) | 1998-04-14 | 2001-06-08 | Coletica | Particule a groupement hydroxamique chelatante d'ions metalliques et leur utilisation en cosmetique ou en pharmacie |
EP1073902A2 (de) * | 1998-04-20 | 2001-02-07 | University Of North Carolina At Chapel Hill | Naonometerpartikel mit reaktiver schicht |
ATE487136T1 (de) | 2000-03-28 | 2010-11-15 | Nanosphere Inc | Nanopartikel mit gebundenen oligonukleotiden und verwendungen derselben |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
-
2000
- 2000-10-16 GB GBGB0025414.4A patent/GB0025414D0/en not_active Ceased
-
2001
- 2001-10-16 AU AU2001294068A patent/AU2001294068B2/en not_active Expired
- 2001-10-16 JP JP2002535642A patent/JP4467882B2/ja not_active Expired - Lifetime
- 2001-10-16 ES ES05026069.4T patent/ES2346319T5/es not_active Expired - Lifetime
- 2001-10-16 AU AU9406801A patent/AU9406801A/xx active Pending
- 2001-10-16 US US10/399,284 patent/US7364919B2/en not_active Expired - Lifetime
- 2001-10-16 CA CA2424734A patent/CA2424734C/en not_active Expired - Lifetime
- 2001-10-16 AT AT01974554T patent/ATE319436T1/de active
- 2001-10-16 AT AT05026069T patent/ATE468112T1/de active
- 2001-10-16 EP EP01974554A patent/EP1326589B1/de not_active Expired - Lifetime
- 2001-10-16 WO PCT/GB2001/004633 patent/WO2002032404A2/en active IP Right Grant
- 2001-10-16 DE DE60117828T patent/DE60117828T2/de not_active Expired - Lifetime
- 2001-10-16 ES ES01974554T patent/ES2262684T3/es not_active Expired - Lifetime
- 2001-10-16 DE DE60142192T patent/DE60142192D1/de not_active Expired - Lifetime
- 2001-10-16 EP EP05026069.4A patent/EP1671625B2/de not_active Expired - Lifetime
-
2008
- 2008-02-29 US US12/040,594 patent/US8080431B2/en not_active Expired - Fee Related
-
2009
- 2009-06-24 JP JP2009150219A patent/JP2009242418A/ja active Pending
-
2011
- 2011-11-29 US US13/306,924 patent/US8790934B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1326589A2 (de) | 2003-07-16 |
EP1671625A1 (de) | 2006-06-21 |
ES2346319T3 (es) | 2010-10-14 |
US7364919B2 (en) | 2008-04-29 |
CA2424734A1 (en) | 2002-04-25 |
US8790934B2 (en) | 2014-07-29 |
EP1326589B1 (de) | 2006-03-08 |
EP1671625B2 (de) | 2013-12-25 |
GB0025414D0 (en) | 2000-11-29 |
ATE319436T1 (de) | 2006-03-15 |
DE60117828D1 (de) | 2006-05-04 |
ATE468112T1 (de) | 2010-06-15 |
JP4467882B2 (ja) | 2010-05-26 |
AU2001294068B2 (en) | 2005-12-22 |
CA2424734C (en) | 2011-10-11 |
JP2009242418A (ja) | 2009-10-22 |
US8080431B2 (en) | 2011-12-20 |
US20120071443A1 (en) | 2012-03-22 |
WO2002032404A2 (en) | 2002-04-25 |
DE60117828T2 (de) | 2006-11-16 |
EP1671625B1 (de) | 2010-05-19 |
ES2346319T5 (es) | 2014-03-18 |
US20040052729A1 (en) | 2004-03-18 |
WO2002032404A3 (en) | 2002-08-22 |
US20080145441A1 (en) | 2008-06-19 |
AU9406801A (en) | 2002-04-29 |
ES2262684T3 (es) | 2006-12-01 |
JP2004511511A (ja) | 2004-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60142192D1 (de) | Nanopartikel | |
DK1631318T3 (da) | Magnetiske nanopartikler bundet til en ligand | |
ATE378399T1 (de) | Magnetische manipulation von biologischen proben | |
ATE236656T1 (de) | Eingeschränktes multifunktionelles reagens zur oberflächenmodifikation | |
CY1109554T1 (el) | Μεθοδοι και αντιδραστηρια για την ανιχνευση ενδοτοξινης | |
DE69434871D1 (de) | Erhöhung von Chemilumineszenz in Assays | |
ATE412774T1 (de) | Parallele genotypisierung mehrerer patientenproben | |
ATE437888T1 (de) | Aus chaperonin-polypeptiden gebildete geordnete biologische nanostrukturen | |
ATE160818T1 (de) | Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit | |
ATE354607T1 (de) | Opake folie aus polymilchsäuren | |
JP2005513440A5 (de) | ||
BRPI0600196A (pt) | ativação de dados de usuário final | |
WO2002061129A3 (en) | Oligonucleotide identifiers | |
Lard et al. | Molecular motor transport through hollow nanowires | |
CO4410395A1 (es) | Procedimiento para la investigacion de la interaccion de biomoleculas mediante resonancia de plasmones en la super- ficie y conjunto o estuche de biosensor para llevar a cabo dicho procedimiento | |
DE50300739D1 (de) | Vorrichtung zur aufnahme von substraten | |
ATE430712T1 (de) | Analyse von molekülen durch translokation durch eine beschichtete öffnung | |
WO2004090506A3 (en) | Surfaces that selectively bind to moieties | |
DE602004005158D1 (de) | Oberflächenschichtsaffinitätschromatographie | |
DE60133937D1 (de) | Vorrichtung zur Herstellung von Mikromatrizen wobei die Vorrichtung in inkrementellen Etappen mechanisch eingestellt wird | |
DE69115518D1 (de) | Verfahren zur Abtrennung und Messung von Spurbestandteilen | |
DE69214244T2 (de) | Monoklonale Antikörper gegen sulfonierte Polymere | |
RS50714B (sr) | Metode za prečišćavanje fsh | |
ATE157283T1 (de) | Aufgetragene mikrokugeln | |
Yeo et al. | Investigation of protein adsorption using plasma treatment for protein chips |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent |